(Q46759815)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18266773%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

title

Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18266773%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Mélanie Roland

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18266773%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Claire Doute

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18266773%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Matthias Büchler

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18266773%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Azmi Al-Najjar

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18266773%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Christelle Barbet

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18266773%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Valérie Chatelet

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18266773%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Jean-Frédéric Marlière

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18266773%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Hubert Nivet

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18266773%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Jean-Michel Halimi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18266773%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

4 February 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18266773%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

published in

Transplant International

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18266773%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18266773%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18266773%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

523-530

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18266773%20AND%20SRC:MED&resulttype=core&format=json

Posttransplantation diabetes: a systematic review of the literature

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Clinical impact of posttransplant diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Relative risk of new-onset diabetes during the first year after renal transplantation in patients receiving tacrolimus or cyclosporine immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Diabetes mellitus after kidney transplantation in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Management of hyperglycaemia after pancreas transplantation: are new immunosuppressants the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Steroid withdrawal in living donor renal transplant recipients using tacrolimus and cyclosporine: a randomized prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Diabetes mellitus after kidney transplantation: a French multicentre observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Disordered Fat Storage and Mobilization in the Pathogenesis of Insulin Resistance and Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2008.00640.X